TABLE 2.
Follow-up data and treatments.
| Merged first, second and third delta MEEI quartiles | Highest delta MEEI quartile improvement | P-value | |
| n = 5,164 | n = 1,723 | ||
| Mean systolic BP during follow up (mmHg) | 137.2 ± 12.7 | 136.9 ± 12.3 | 0.387 |
| Mean diastolic BP during follow up (mmHg) | 84.3 ± 7.4 | 84.4 ± 7.0 | 0.432 |
| Mean pulse pressure during follow up (mmHg) | 53.5 ± 12.5 | 53.6 ± 12.6 | 0.75 |
| Mean heart rate during follow up (bpm) | 75.3 ± 8.0 | 73.0 ± 7.6 | 0.199 |
| Mean body mass index during follow up (kg/m2) | 27.8 ± 5.1 | 27.6 ± 4.9 | 0.027 |
| Weight loss (%) | 810 (15.7) | 301 (17.5) | 0.082 |
| Mean weight during follow up (kg) | 78.4 ± 14.2 | 77.3 ± 13.3 | 0.003 |
| Mean fasting plasma glucose during follow up (mg/dl) | 100.4 ± 21.7 | 98.8 ± 17.7 | 0.005 |
| Mean serum total cholesterol during follow up (mg/dl) | 200.4 ± 32.9 | 200.5 ± 32.5 | 0.859 |
| Mean serum HDL cholesterol during follow up (mg/dl) | 50.8 ± 11.5 | 51.9 ± 11.5 | 0.001 |
| Mean serum triglycerides during follow up (mg/dl) | 133.2 ± 62.2 | 128.4 ± 57.8 | 0.005 |
| Mean serum uric acid during follow up (mg/dl) | 5.2 ± 1.3 | 5.2 ± 1.2 | 0.833 |
| Mean METS-IR during follow up | 41.6 ± 9.0 | 40.7 ± 8.6 | < 0.0001 |
| Mean CKD-EPI during follow up | 79.3 ± 14.2 | 80.0 ± 13.7 | 0.078 |
| LV mass index at the end of follow up (g/m2.7) | 48.0 ± 9.1 | 47.0 ± 9.0 | < 0.0001 |
| LV mass index reduction at the end of follow up (%) | 261 (5.1) | 218 (12.7) | < 0.0001 |
| Relative wall thickness at the end of follow up | 0.39 ± 0.04 | 0.38 ± 0.03 | < 0.0001 |
| Left atrial volume index at the end of follow up (ml/m2) | 14.1 ± 2.9 | 13.9 ± 2.6 | 0.107 |
| Stroke volume index at the end of follow up (ml/m2) | 39.6 ± 4.9 | 40.8 ± 4.7 | < 0.0001 |
| LVEF at the end of follow up (%) | 66.0 ± 3.8 | 67.3 ± 3.6 | < 0.0001 |
| LVEF reduction (%) | 83 (1.6) | 6 (0.3) | < 0.0001 |
| MEEI at the end of follow up (mL/s/g) | 0.32 ± 0.06 | 0.38 ± 0.06 | < 0.0001 |
| Intima-media thickness at the end of the follow up (mm) | 1.78 ± 0.78 | 1.71 ± 0.74 | 0.001 |
| BP control at the end of the follow up (%) | 2,952 (57.2) | 1,015 (58.9) | 0.216 |
| Medication at least 50% of control visits | 1.64 ± 1.03 | 1.64 ± 1.04 | 0.921 |
| Beta blockers | 1,246 (24.1) | 561 (32.6) | < 0.0001 |
| Anti-renin-angiotensin-aldosterone system | 4,221 (81.7) | 1,399 (81.2) | 0.615 |
| Diuretics | 2,229 (43.2) | 737 (42.8) | 0.779 |
| dihydropyridine Calcium channel blockers | 1,383 (26.8) | 395 (22.9) | 0.001 |
| Statins | 929 (18.3) | 325 (19.2) | 0.517 |
| Antiplatelet therapy | 894 (17.6) | 261 (15.3) | 0.028 |
BP, blood pressure; CKD-EPI, chronic kidney disease epidemiology collaboration; LV, left ventricular; LV EF, left ventricular ejection fraction; MEEi, mechano-energetic efficiency indexed for myocardial mass.